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Dextrin is a biocompatible polysaccharide that can be suited for the 
conjugation with bioactive agents while enabling controlled release 
at the target site. LLKKK18, an LL37 human cathelicidin analog, has 
been engineered to enhance antimicrobial properties and decrease 
toxicity. In this work, chemically modified dextrin bearing a 
carboxylic group has been produced to allow the conjugation with 
LLKKK18 for the treatment of osteomyelitis. FT-IR spectra 
confirmed dextrin modification while maximum degradability was 
achieved after approximately 2h. A batch of 30% mol modification 
was used to conjugate with LLKKK18 and incubated in vitro with 
Staphylococcus aureus. Conjugates incubated with α-amylase were 
more effective in killing bacteria when compared to conjugates with 
intact bonds, emphasizing the protective effect of dextrin and 
indicating a controlled peptide release. 
 
Dextrin is glucose polymer, generally regarded as safe 
(GRAS), obtained from partial hydrolysis of starch. It is a 
biocompatible material, non-immunogenic and degradable in 
vivo by α-amylases. Regarding the biomedical field, the 
polymer has been shown to envelope a protein thus masking its 
bioactivity, while enabling controlled restoration of activity at 
the target site by triggered polymer degradation [1]. Moreover, 
in previous work, we have demonstrated the conjugation of the 
antimicrobial LLKKK18 peptide with a carboxyl group created 
in the dextrin backbone [2]. 
 
Antimicrobial peptides (AMPs) are part of the innate immune 
system with potential as novel therapeutic agents due to its 
high spectrum of antimicrobial activity and low propensity for 
bacteria to developing resistance [3]. The bactericidal effect of 
LL37, the only known human cathelicidin, has been reported 
[4]. LLKKK18, an LL37 analog, has been engineered to 
enhance antimicrobial properties and decrease toxicity, being 
three-fold more effective in the killing of mycobacteria than 
LL37. Despite these advantages, exogenous administration is 
limited by enzymatic degradation, ultimately leading to an 
unsuccessful local delivery of AMPs. 
 
Osteomyelitis is an inflammation of the bone triggered by an 
infection, which results in inflammatory destruction and tissue 
necrosis. The antimicrobial effect of LLKKK18 associated to a 
proper nanocarrier, emerges as an innovative and promising 
solution to treat this pathological condition. 
 
In this work we hypothesized that the modified polymer would 
be slowly degraded by amylases, releasing the peptide in a 
controlled fashion avoiding its early degradation, thus 
improving antimicrobial effectiveness. The activity of the 
conjugates obtained was assessed in vitro, using a relevant  
 
 
strain mostly responsible for osteomyelitis, Staphylococcus 
aureus.  
 
Dextrin was succinoylated using a modified version of a 
previously described method [5], based on the introduction of a 
carboxyl group in the dextrin backbone via an ester linkage, in 
a 4-dimethylaminopyridine (DMAP)-catalyzed reaction. The 
ratio of reagents used was optimized to yield a modified 
dextrin that: (a) would have enough functional groups to bind 
LLKKK18, and (b) would be able to delay degradation by 
amylases in order to provide a sustained release of the peptide. 
Modification % of several batches was confirmed by FT-IR 
and quantified by titration with sodium hydroxide. 
Succinoylated dextrin (DexSuc) spectrum showed a 
transmittance peak around 1729 cm-1 that is typical for the ester 
groups inserted in the dextrin backbone [6], while being absent 
in the unmodified dextrin. Titration allowed the quantification 
of the degree of substitution of batches with different degrees 
of succinoylation. In general, DexSuc degradation by 
dinitrosalicylic colorimetric method took around 2h, and 
increasing % modification slowed the degradation rate. 
LLKKK18 was then conjugated with dextrin [5], based on the 
binding of the peptide free amines to the free carboxyl groups 
in the succinoylated dextrin backbone, which results in the 
formation of an amide (as shown in the Graphical Abstract). 
 
In vitro studies with S. aureus showed that incubation of 
conjugates with α-amylase increased the microbicidal activity 
as compared to intact conjugates, emphasizing the protective 
effect of dextrin and indicating a controlled peptide release. In 
fact, conjugates with α-amylase and intact conjugates 
corresponding to a peptide concentration of 1.17 µg/mL, were 
able to reduce viability to 0% and 32.8%, respectively. 
These results are promising and will soon be further 
investigated in a rat model of osteomyelitis. 
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